TCGA-55-8621-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.430
- IL6_JAK_STAT3_SIGNALING+0.420
- MYOGENESIS+0.390
- COMPLEMENT+0.370
- INFLAMMATORY_RESPONSE+0.370
- ALLOGRAFT_REJECTION+0.360
- APICAL_SURFACE+0.350
- COAGULATION+0.340
- BILE_ACID_METABOLISM+0.330
Top 10 suppressed
- E2F_TARGETS-0.740
- MYC_TARGETS_V1-0.740
- MYC_TARGETS_V2-0.700
- G2M_CHECKPOINT-0.640
- OXIDATIVE_PHOSPHORYLATION-0.570
- MTORC1_SIGNALING-0.520
- UNFOLDED_PROTEIN_RESPONSE-0.510
- DNA_REPAIR-0.490
- GLYCOLYSIS-0.430
- PROTEIN_SECRETION-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.961 |
| 2 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.954 |
| 3 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.948 |
| 4 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.940 |
| 5 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.940 |
| 6 | SRR2665516 | — | — | 0.938 |
| 7 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.938 |
| 8 | SRR26320092 | — | — | 0.935 |
| 9 | TCGA-75-6203-01A-11R-1755-07 | — | cohortA1 | 0.934 |
| 10 | 20040019.LumA | — | A | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |